Diamyd Medical AB (publ) (DMYD_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to BioStock. In today's live broadcast we will be talking about Bookstore Communiqué and we will do that together with DMU Medical and VD Ulf Hanedius. There is an opportunity to ask questions to Ulf in the open chat, but before we get to the question section, we will listen to a short presentation from Ulf. And before we do that, of course, we will say welcome to Ulf. Hi Ulf. Thank you very much. Nice to have you here. Very nice to have you here. Before I let you start your presentation, I would like to ask two short questions. The first one is, could you just summarize the three most important events from this reporting period? Three most important. If we think regulatory and on the clinic side, it is most important that we are now at the end of the track with patient recruitment. In the FAST-3 study, we have been 275 patients So we plan to end the screening for new patients this year. We are also preparing for the early reading that is expected in March next year. So in six months we will have an early reading from the FAST-3 study that can lay the groundwork for an accelerated approval in the USA. In terms of manufacturing and science, we also have our facility in Umeå on track to get GMP certification. We have been in contact with Läkemedelsverket now and we expect their feedback in the coming months on this work. And scientifically, we were also presented at EASD, one of the largest diabetes fairs recently, with new analyses that strengthen our case around our drug testing and the effect it has on diabetes. And last but not least, it has been one of the most difficult financial markets so far. For a long time, we have managed to bring in money in a very cost-effective way, at about 315 million kronor during the year. So it really shows strengt...